In brief: Cytopia, Visiomed
Wednesday, 27 April, 2005
Cytopia (ASX:CYT) has received ethics approval to begin a Phase I clinical trial of its anti-cancer drug CYT997 at at the Royal Brisbane and Women's Hospital. The trial will be conducted in association with the Queensland Institute of Medical Research and Q-Pharm. Cytopia chief scientific officer Andrew Wilks said that the 30-patient trial would be a non-blinded, dose escalation study in patients with various cancers and could take between nine and twelve months.
Visiomed has received an initial purchase order for approximately 1500 Funhaler asthma spacers from its Australian distributor, Cottman Australia, a subsidiary of Advance Healthcare Group Limited (ASX:AHG). The order will take up 100 per cent of the Visiomed's first production run.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
